Cargando…

Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development

OBJECTIVE: Patients identified as black and from disadvantaged backgrounds have a twofold higher hydroxychloroquine (HCQ) non-adherence, which contributes to worse lupus outcomes and disparities. Yet, most adherence interventions lack tailored strategies for racially and socioeconomically diverse pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garg, Shivani, Chewning, Betty, Gazeley, David, Gomez, Shelby, Kaitz, Noah, Weber, Amanda C, Rosenthal, Ann, Bartels, Christie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345084/ https://www.ncbi.nlm.nih.gov/pubmed/35914839 http://dx.doi.org/10.1136/lupus-2022-000720

Ejemplares similares

Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards
por: Garg, Shivani, et al.
Publicado: (2023)

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Rheumatologists’ perspective on hydroxychloroquine guidelines
por: Winebrake, James, et al.
Publicado: (2020)

Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety
por: Cornet, Alain, et al.
Publicado: (2021)

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus
por: Vázquez-Otero, Ileana, et al.
Publicado: (2020)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research
por: Tse, Karin, et al.
Publicado: (2021)

Perceptions of racism in healthcare among patients with systemic lupus erythematosus: a cross-sectional study
por: Vina, Ernest R, et al.
Publicado: (2015)

Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort
por: Albrecht, Katinka, et al.
Publicado: (2021)

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA
por: Bell, Christopher F, et al.
Publicado: (2020)

Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance
por: Ploran, Elisabeth, et al.
Publicado: (2019)

Identification and assessment of classification criteria attributes for systemic lupus erythematosus in a regional medical record data network
por: Forrest, Noah, et al.
Publicado: (2023)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study
por: Scolnik, M, et al.
Publicado: (2014)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Patients with overlap autoimmune disease differ from those with ‘pure’ disease
por: Lockshin, Michael D, et al.
Publicado: (2015)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments
por: Askanase, Anca, et al.
Publicado: (2015)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort
por: Fischin, Julia, et al.
Publicado: (2015)

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s
por: Albrecht, Katinka, et al.
Publicado: (2014)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
por: Croyle, Lucy, et al.
Publicado: (2015)

Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis
por: Bernal-Macías, Santiago, et al.
Publicado: (2015)

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus
por: Utset, Tammy O, et al.
Publicado: (2015)

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy
por: Robinson, Angela Byun, et al.
Publicado: (2014)

Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy
por: Robinson, Angela Byun, et al.
Publicado: (2014)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
por: Kazzaz, Nayef M, et al.
Publicado: (2015)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
por: Kheir, Joseph M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6gcgqrkefr6mbf2li0hmjd0f9a